Lyra Therapeutics, Inc. (LYRA) NASDAQ

7.20

+0.1478(+2.10%)

Updated at August 18 02:47PM

Currency In USD

Valuation

Market Cap671.98M
Enterprise Value665.78M
P/E Ratio-0.25
PEG Ratio0
Price/Sales Ratio15.37
Price/Book Ratio5.98
Enterprise/Revenue18.87
Enterprise/EBITDA-0.42

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterJune 30, 2025

Profitability

Profit Margin-50.44
Operating Margin-53.4

Management Effectiveness

Return On Assets-0.74
Return On Equity-4.12

Income Statement

Revenue1.53M
Revenue/Share0.57
Gross Profit1.53M
EBITDA-60.26M
Net Income-93.44M
Diluted EPS-1.43

Balance Sheet

Total Cash29.78M
Total Cash/Share22.08
Total Debt32.48M
Total Debt/Equity20.02
Current Ratio2.78
Book Value Per Share1.2

Price History

52-Week Change-53.86
52-Week High37.5
52-Week Low3.81
Moving Average 50 Days9.81
Moving Average 200 Days9.06

Statistics

Average Volume660,802
Shares Outstanding1.64M
% Held by Institutions36.63

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor1:50
Last Split DateMay 28, 2025